GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET

Company Participants

Gabrielle DeGravina – Investor Relations-CG Capital

David Dodd – Chairman and Chief Executive Officer

Mark Reynolds – Chief Financial Officer

Kelly McKee – Chief Medical Officer

John Sharkey – Vice President-Business Development

Mark Newman – Chief Scientific Officer

Conference Call Participants

Robert LeBoyer – Noble Capital Markets

Kumar Raja – ROTH Capital

Jeffrey Kraws – Crystal Research Associates

Operator

Good day. My name is Jordan and I will be your conference operator today. At this time I would like to welcome everyone to the GeoVax Second Quarter Earnings Conference Call.

I will turn the call over to Gabrielle.

Gabrielle DeGravina

Thank you. Please note the following. Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner and such products will be safe for human use. GeoVax's vaccines will effectively prevent targeted infections in humans. GeoVax's product candidates will receive regulatory approvals necessary to be licensed and marketed. GeoVax raises required capital to complete vaccine development of its products. There is development of competitive products that maybe more effective or easier to use than GeoVax's products. GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission, including those set forth at risk factors in GeoVax's Form 10-K.

It is now my pleasure to introduce the Chairman and CEO of GeoVax, David Dodd.

David Dodd

Good afternoon, and thank you for participating in the GeoVax corporate update call. This year we have expanded patient enrollment in support of the Gedeptin Phase 2 clinical trial and the two phase two trials for GEO CMO4S1, as well as announcing the initiation of the third Phase 2 clinical program, evaluating this next-generation COVID-19 vaccine as a booster among patients with chronic lymphocytic leukemia. We also recently expanded our rights related to CMO4S1 to include Omicron variants, monkeypox and smallpox further differentiating our COVID-19 vaccine. While the clinical development progress of Gedeptin and the CMO4S1 one remain our priority, we're also focused on GEO-MVA, our vaccine against monkeypox and smallpox, as well as the implementation of the transformative MVA continuous cell line manufacturing process.